SCHEMBL17857128

SCHEMBL17857128

CN1CCN(Cc2c(N)cccc2C(F)(F)F)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
KDM4E B2RXH2 4/20 0.55
POLB P06746 2/20 0.55
NR1H2 P55055 1/20 0.55
PIK3CD O00329 2/20 0.46
PIK3C2B O00750 2/20 0.46
MTOR P42345 2/20 0.46
PIK3CG P48736 2/20 0.46
PIK3CA P42336 1/20 0.46
PIK3CB P42338 1/20 0.46
LMNA P02545 1/20 0.44
CHKA P35790 2/20 0.43
CA2 P00918 1/20 0.43
NCF1 P14598 1/20 0.43
PRMT6 Q96LA8 1/20 0.43
MC4R P32245 1/20 0.42
TSHR P16473 1/20 0.42
ATM Q13315 2/20 0.42
NPSR1 Q6W5P4 2/20 0.41
KMT2A Q03164 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19760594 0.86 KDM4E (0.48) ALDH1A1KDM4EPOLBNR1H2PIK3CD
SCHEMBL17857246 0.83 KMT2A (0.62) ALDH1A1KDM4EPOLBNR1H2PIK3CD
SCHEMBL19760571 0.82 CYP2A13 (0.50) ALDH1A1KDM4EPIK3CDPIK3C2BMTOR
SCHEMBL28847349 0.80 KDM4E (0.49) ALDH1A1KDM4EPOLBNR1H2TSHR
SCHEMBL28262408 0.78 KDM4E (0.50) ALDH1A1KDM4EPOLBNR1H2MC4R
SCHEMBL19760590 0.78 PIK3CD (0.51) ALDH1A1KDM4EPIK3CDPIK3C2BPIK3CG
SCHEMBL5273771 0.77 ALDH1A1 (0.48) ALDH1A1KDM4EPOLBLMNACHKA
SCHEMBL19760591 0.77 SIRT6 (0.50) ALDH1A1KDM4EPOLBNR1H2LMNA
SCHEMBL21119870 0.77 DRD3 (0.38) ALDH1A1KDM4EPOLBPIK3CDPIK3C2B
SCHEMBL5498471 0.77 ALDH1A1 (0.55) ALDH1A1KDM4EPOLBNR1H2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233862-B1 IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2019-07-03 EP disclosed
US-20180002336-A1 IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-01-04 US disclosed
WO-2016097347-A1 IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2016-06-23 WO disclosed
CN-101304747-A Combinations comprising a VEGF receptor inhibitor and a penetration enhancer NOVARTIS AG (CH) 2008-11-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180002336-A1 IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS PIK3CB, PIK3CD, PIK3CA ALDH1A1 1344/4885KDM4E 1866/4885POLB 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.